Alnylam Pharmaceuticals

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference.

CEO

Yvonne L. Greenstreet

CEOYvonne L. Greenstreet

Employees

2,230

Employees2,230

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2002

Founded2002

Employees

2,230

Employees2,230

ALNY Key Statistics

Market cap

32.81B

Market cap32.81B

Price-Earnings ratio

-123.44

Price-Earnings ratio-123.44

Dividend yield

—

Dividend yield—

Average volume

1.08M

Average volume1.08M

High today

$259.92

High today$259.92

Low today

$251.32

Low today$251.32

Open price

$259.92

Open price$259.92

Volume

372.12K

Volume372.12K

52 Week high

$304.39

52 Week high$304.39

52 Week low

$144.73

52 Week low$144.73

ALNY News

Simply Wall St 3d

Alnylam Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations

Alnylam Pharmaceuticals ( ) First Quarter 2025 Results Key Financial Results Revenue: US$594.2m (up 20% from 1Q 2024). Net loss: US$57.5m (loss narrowed by 1...

Benzinga 7d

Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk

Alnylam Pharmaceuticals Inc ALNY on Thursday reported a first-quarter 2025 adjusted EPS loss of 1 cent, beating the consensus loss of $(1.03). The company repo...

Analyst ratings

74%

of 35 ratings

Buy

74.3%

Hold

22.9%

Sell

2.9%

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.

Vertex Pharmaceuticals